RxDoctor Payments Data

Karan Desai, MD

Cardiovascular Disease · Leesburg, VANPI 1538555909

Payments from drug & device makers

$2,549in general payments, 2019–2025

Across 43 payments — averaging $59.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novartis$190
  • Pfizer$109
  • Edwards Lifesciences$76
  • Scpharmaceuticals Inc.$66
  • AstraZeneca$54
  • plus $432 from 15 others

What the payments were for

  • Food & beverage$944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,549 in reported general payments places this provider in the 60th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$193,390
Medicare patients
1,620
Services billed
3,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$70,581
JardianceEmpagliflozin20$33,416
EntrestoSacubitril/Valsartan24$26,416
FarxigaDapagliflozin Propanediol11$8,192
Metoprolol Succinate110$2,014
Dabigatran EtexilateDabigatran Etexilate Mesylate12$1,826
Ezetimibe37$1,745
Atorvastatin Calcium73$1,097
Rosuvastatin Calcium53$1,030
Potassium Chloride22$469
Amlodipine Besylate44$451
Torsemide20$442
Valsartan16$385
Lisinopril33$358
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$70,58166 claims
Boehringer IngelheimJardiance$53$33,41620 claims
NovartisEntresto$190$26,41624 claims
AstraZenecaFarxiga$54$8,19211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →